news-med.jpg

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Topics: Corporate, Acquisition, Drug Development, Drug Discovery, Contract Reseach Organization, Partner Research Organization, Integrated CMC, IND Enabling Read More

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance

Read the article on antimicrobial resistance from our very own Antonio Felici, which was published in Bioscience Technology this month. Read full article from Bioscience Technology online site

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery Read More

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address ...

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery, Gram-negative bacteria, Partner Research Organization Read More

Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery London, Boston, Greenwich - February 28, 2017 – The ...

Topics: Drug design and discovery, Hit Discovery, Drug Discovery, Dementia Drug Discovery, Computational Chemistry, Compound Logistics, Assay Development Read More